Search - tctmd.com

Displaying 1 - 20 of 722

Sort: Relevancy | Date

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Daily News

CMS Greenlights Reimbursement for Renal Denervation Systems

L.A. McKeown

October 29, 2025

Presentation TCT 2025

First Report of the SPYRAL AFFIRM Study: Reduced Home and Office Blood Pressure Following Radiofrequency Renal Denervation in a Large US Cohort of High Cardiovascular Risk Patients.

Presenter: Felix Mahfoud

October 27, 2025

Presentation TCT 2025

TCT 591: High Diastolic Blood Pressure as a Predictor of Limitation of Cerebroprotective Effects of Renal Denervation

Presenter: Alla Falkovskaya

October 27, 2025

Presentation TCT 2025

TCT 592: INTRAVASCULAR ULTRASOUND-GUIDED DRUG ELUTING STENTING FOR RENAL ARTERY STENOSIS: SINGLE CENTER PILOT STUDY 2017-2023

Presenter: Muhammad Haisum Maqsood

October 27, 2025

Presentation TCT 2025

TCT 1917: Challenging Case of Repeat Renal Denervation for Uncontrolled Hypertension

Presenter: Mina Madan

October 27, 2025

Presentation TCT 2025

TCT 590: Single-Center Real world use of the Paradise Renal Denervation Catheter. Early experience from the Cleveland Clinic.

Presenter: Anmol Multani

October 27, 2025

Presentation TCT 2025

TCT 588: 24-Month Durability of the Blood Pressure Lowering Effect of Ultrasound Renal Denervation for Hypertension with the Paradise System

Presenter: Ajay J. Kirtane

October 27, 2025

Presentation TCT 2025

Renal Denervation is FDA Approved - Will it Ever Be First Line Therapy?

Presenter: David P. Lee

October 27, 2025

Presentation TCT 2025

Where Do We See Renal Denervation in the Hypertension Pathway, Now and in Five Years?

Presenter: David E. Kandzari

October 27, 2025

Presentation TCT 2025

TCT 589: Same Day Discharge with the Symplicity Renal Denervation System: Outcomes from the Real World Global Symplicity Registry DEFINE

Presenter: Joachim Weil

October 27, 2025

Presentation TCT 2025

TCT 584: Renal Denervation for Resistant Hypertension in Fibromuscular Dysplasia: A Case Series

Presenter: Merlin Nikita

October 27, 2025

Presentation TCT 2025

TCT 583: Long-term Safety and Efficacy of Renal Sympathetic Denervation in Patients with Heart Failure with Reduced Ejection Fraction: 5-year results from the IMPROVE-HF-I study

Presenter: Kari A. Saville

October 27, 2025

Presentation TCT 2025

TCT 582: Ultrasound vs. Radiofrequency Renal Denervation: A Comparative Analysis

Presenter: Anmol Multani

October 27, 2025

Presentation TCT 2025

TCT 581: Renal Sympathetic Denervation as Adjunctive Upstream Therapy during Atrial Fibrillation Ablation: Pooled Analysis of the HFIB and Ultra-HFIB Studies

Presenter: Vivek Y. Reddy

October 27, 2025

Presentation TCT 2025

TCT 585: Renal Denervation Combined with Atrial Fibrillation Ablation in Heart Failure: Interim 6-Month Data on Reverse Remodeling and Arrhythmia Recurrence

Presenter: Tomasz Skowerski

October 27, 2025

Presentation TCT 2025

TCT 586: Diuretic Management in Patients Treated with Greater Splanchnic Nerve Ablation for HFpEF: REBALANCE-HF Randomized Trial

Presenter: Sheldon E. Litwin

October 27, 2025

Presentation TCT 2025

TCT 577: Efficacy and Safety of Ultrasound-Based Renal Denervation in Patients with Autosomal Dominant Polycystic Kidney Disease: Results from the RDN-ADPKD study

Presenter: Roland E. Schmieder

October 27, 2025

Presentation TCT 2025

TCT 578: Temporal Trends and Mortality Patterns of Hypertension and Metabolic Disorders in the U.S: A CDC-Based Study (1999–2020)

Presenter: Zoha Mujtaba

October 27, 2025

Presentation TCT 2025

TCT 580: Initial, Prospective Analysis of Uncontrolled Hypertensive Patients Included in the Global Paradise System (GPS) Registry Outside of the United States

Presenter: Karl Fengler

October 27, 2025

Advertisement

What’s Going to Be Hot at AHA 2025?

CMS Greenlights Reimbursement for Renal Denervation Systems

First Report of the SPYRAL AFFIRM Study: Reduced Home and Office Blood Pressure Following Radiofrequency Renal Denervation in a Large US Cohort of High Cardiovascular Risk Patients.

TCT 591: High Diastolic Blood Pressure as a Predictor of Limitation of Cerebroprotective Effects of Renal Denervation

TCT 592: INTRAVASCULAR ULTRASOUND-GUIDED DRUG ELUTING STENTING FOR RENAL ARTERY STENOSIS: SINGLE CENTER PILOT STUDY 2017-2023

TCT 1917: Challenging Case of Repeat Renal Denervation for Uncontrolled Hypertension

TCT 590: Single-Center Real world use of the Paradise Renal Denervation Catheter. Early experience from the Cleveland Clinic.

TCT 588: 24-Month Durability of the Blood Pressure Lowering Effect of Ultrasound Renal Denervation for Hypertension with the Paradise System

Renal Denervation is FDA Approved - Will it Ever Be First Line Therapy?

Where Do We See Renal Denervation in the Hypertension Pathway, Now and in Five Years?

TCT 589: Same Day Discharge with the Symplicity Renal Denervation System: Outcomes from the Real World Global Symplicity Registry DEFINE

TCT 584: Renal Denervation for Resistant Hypertension in Fibromuscular Dysplasia: A Case Series

TCT 583: Long-term Safety and Efficacy of Renal Sympathetic Denervation in Patients with Heart Failure with Reduced Ejection Fraction: 5-year results from the IMPROVE-HF-I study

TCT 582: Ultrasound vs. Radiofrequency Renal Denervation: A Comparative Analysis

TCT 581: Renal Sympathetic Denervation as Adjunctive Upstream Therapy during Atrial Fibrillation Ablation: Pooled Analysis of the HFIB and Ultra-HFIB Studies

TCT 585: Renal Denervation Combined with Atrial Fibrillation Ablation in Heart Failure: Interim 6-Month Data on Reverse Remodeling and Arrhythmia Recurrence

TCT 586: Diuretic Management in Patients Treated with Greater Splanchnic Nerve Ablation for HFpEF: REBALANCE-HF Randomized Trial

TCT 577: Efficacy and Safety of Ultrasound-Based Renal Denervation in Patients with Autosomal Dominant Polycystic Kidney Disease: Results from the RDN-ADPKD study

TCT 578: Temporal Trends and Mortality Patterns of Hypertension and Metabolic Disorders in the U.S: A CDC-Based Study (1999–2020)

TCT 580: Initial, Prospective Analysis of Uncontrolled Hypertensive Patients Included in the Global Paradise System (GPS) Registry Outside of the United States

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content